Anavex Life Sciences Corp (AVXL)

[falconer66a]

When retail investors learn the story.

Eventually, momentum will return to AVXL and volume buying will return.

See if I’m right.

So far, the general retail equity investor community has never heard a word about some “Anavex” company. Consequently, market makers and institutional market players can exert predominating controls over the AVXL share price.

That will change (check for this) when the New York Times comes out with an article, to the effect: “New drug fixes rare CNS disease, Parkinson’s and Alzheimer’s diseases next.”

That article can’t be written until the very favorable results appear from the Rett syndrome clinical trial is completed, apparently some time late this year or early next year. The Rett results can’t be dismissed. The trial is a big double-blind trail (placebo arm and research arm), with enough participants to make all findings statistically significant; authentic, not by random chance.

The writer of the article will have to explain what “Rett syndrome” is. It will be noted that it is a tragic, rare genetic disease with an extremely poor prognosis; in the central nervous system. Everyone knows that CNS diseases don’t lend themselves to pharmaceutical ameliorations. Same with genetically-based diseases. If born with it, very little can be done. Rett syndrome has a therapeutic double-whammy; in the central nervous system (nerves), and is genetically-based. No drug can change the bad chromosomes. No hope.

But blarcamesine will be therapeutic; will significantly reduce both Rett symptoms and its progression. It’s the kind of story the Times will delight in telling (“All the news that’s fit to print.”). It won’t be lost in retail equity investors. Because the “new drug” (blarcamesine) is fixing a rare genetic disease, in the CNS, readers will read with scrutiny, even skepticism. But facts from the trial will prevail. Blarcamesine, safely, fixes to some degree (perhaps greatly) profound genetic defects in a CNS disease. Of course, the Anavex media release will make a claim that the Rett results “are expected also in the Parkinson’s disease dementia and Alzheimer’s trials.”

Let’s watch. 2022 looks to be the Anavex Year.